Business information > Business articles > Industry news > Business & Finance newsletters > Pharma Marketletter > July 2004

J&J's Levaquin gets FDA OK for new use.(Johnson & Johnson)(Brief Article)

Article from: Pharma Marketletter | July 26, 2004 | Copyright

Johnson & Johnson's Ortho-McNeil Pharmaceutical unit has received US Food and Drug Administration approval for Levaquin (levofloxacin), in both tablet and injectable forms, for the treatment of multi-drug resistant strains of Streptococcus pneumoniae …

Read all of this article – and millions more – with a FREE, 7-day trial!

Related newspaper, magazine, and journal articles

Bayer HealthCare and Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson Company, Announce Collaborative Development and License Agreement for Antithrombosis Drug; Cooperation for Factor Xa-Inhibitor, BAY 59-7939.
CNW Group; October 26, 2005; 700+ words

...Bayer HealthCare (BHC) and Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, announced today that they have...to further develop this drug together with Johnson & Johnson," said Werner Wenning, Chairman...

J&J unit pleads guilty to improper Topamax marketing.(Litigation)(Johnson & Johnson's Ortho-McNeil Pharmaceutical)
Adverse Event Reporting News; June 1, 2010; 700+ words

Officials of Johnson & Johnson's Ortho-McNeil Pharmaceutical pleaded guilty May 21 in federal court in Boston to...Ortho-McNeil-Janssen Pharmaceuticals, another Johnson & Johnson unit, will pay $75.37 million to resolve...

Basilea Pharmaceutica AG, of Basel, Switzerland, is negotiating with Ortho-McNeil Pharmaceutical Inc., a subsidiary of Johnson & Johnson, of New Brunswick, N.J., concerning a licensing deal for its cephalosporin antibiotic, ceftobiprole (BAL5788).(Other News To Note)(Brief Article)
BioWorld International; December 22, 2004; 232 words

* Basilea Pharmaceutica AG, of Basel, Switzerland, is negotiating with Ortho-McNeil Pharmaceutical Inc., a subsidiary of Johnson & Johnson, of New Brunswick, N.J., concerning a licensing deal for its cephalosporin antibiotic...

7TM Pharma A/S, of Horsholm, Denmark, entered an agreement with Ortho-McNeil Pharmaceutical Inc., a subsidiary of Johnson & Johnson, of New Brunswick, N.J., concerning a drug discovery program based on finding antagonists to a particular 7-transmembrane receptor target.(Other News To Note)(Brief Article)
BioWorld International; June 15, 2005; 269 words

7TM Pharma A/S, of Horsholm, Denmark, entered an agreement with Ortho-McNeil Pharmaceutical Inc., a subsidiary of Johnson & Johnson, of New Brunswick, N.J., concerning a drug discovery program based on finding antagonists...

Collaboration Initiated to Develop New Drugs.(Maxia Pharmaceutical Inc., R.W. Johnson Pharmaceutical Research Institute, and Ortho-McNeil Pharmaceutical Inc. to develop insulin sensitizers for type 2 diabetes)
Genomics & Genetics Weekly; January 26, 2001; 289 words

...announced that it has initiated a multi-year collaboration with The R.W. Johnson Pharmaceutical Research Institute (PRI) and Ortho-McNeil Pharmaceutical, Inc. (OMP) to discover and develop insulin sensitizers for the treatment...

Collaboration Initiated to Develop New Drugs.(Maxia Pharmaceuticals Inc. has collaboration with R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical Inc.)
Biotech Week; January 24, 2001; 287 words

Collaboration Initiated to Develop New Drugs.(Maxia Pharmaceuticals Inc. to collaborate with The Robert Wood Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical Inc.)
Obesity, Fitness & Wellness Week; January 27, 2001; 292 words

BioCryst, J&J Ending Deal For Late-Stage Flu Product.(flu treatment RWJ-270201 license terminated)(BioCryst Pharmaceuticals Inc.; Ortho-McNeil Pharmaceutical Inc.; R.W. Johnson Pharmaceutical Research Institute)(Brief Article)
BioWorld Week; March 7, 2001; 385 words

...Pharmaceuticals Inc. received notice from Ortho-McNeil Pharmaceuticals Inc. and R.W. Johnson Pharmaceutical Research Institute that the Johnson & Johnson companies were terminating their worldwide license agree ment for the flu treatment product...

Search HighBeam Business for more related articles

About us Contact us Terms and conditions Privacy policy

Arrive Prepared – our blog about business news and market research.